JP2015512420A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512420A5 JP2015512420A5 JP2015503653A JP2015503653A JP2015512420A5 JP 2015512420 A5 JP2015512420 A5 JP 2015512420A5 JP 2015503653 A JP2015503653 A JP 2015503653A JP 2015503653 A JP2015503653 A JP 2015503653A JP 2015512420 A5 JP2015512420 A5 JP 2015512420A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- hyperalgesia
- drug
- peripheral neuropathy
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
- 208000004454 Hyperalgesia Diseases 0.000 claims description 15
- 208000035154 Hyperesthesia Diseases 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 9
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 8
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 8
- 229960004528 vincristine Drugs 0.000 claims description 8
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 8
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 claims description 4
- 229960000473 altretamine Drugs 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960000684 cytarabine Drugs 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 229960003668 docetaxel Drugs 0.000 claims description 4
- 229960005237 etoglucid Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 229960004635 mesna Drugs 0.000 claims description 4
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims description 4
- 229960001907 nitrofurazone Drugs 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical group CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 4
- 229960000624 procarbazine Drugs 0.000 claims description 4
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 4
- 229960005314 suramin Drugs 0.000 claims description 4
- 229960001603 tamoxifen Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 1
- -1 Musuchin Chemical compound 0.000 claims 1
- 241001495452 Podophyllum Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 229960003087 tioguanine Drugs 0.000 claims 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261618428P | 2012-03-30 | 2012-03-30 | |
| US61/618,428 | 2012-03-30 | ||
| PCT/US2013/034647 WO2013149172A1 (en) | 2012-03-30 | 2013-03-29 | Methods and compositions for the prevention and treatment neuropathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018063574A Division JP2018123143A (ja) | 2012-03-30 | 2018-03-29 | 神経障害を予防および処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512420A JP2015512420A (ja) | 2015-04-27 |
| JP2015512420A5 true JP2015512420A5 (https=) | 2016-05-26 |
| JP6317324B2 JP6317324B2 (ja) | 2018-04-25 |
Family
ID=49261299
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503653A Active JP6317324B2 (ja) | 2012-03-30 | 2013-03-29 | 神経障害を予防および処置するための方法および組成物 |
| JP2018063574A Pending JP2018123143A (ja) | 2012-03-30 | 2018-03-29 | 神経障害を予防および処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018063574A Pending JP2018123143A (ja) | 2012-03-30 | 2018-03-29 | 神経障害を予防および処置するための方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US9636378B2 (https=) |
| EP (3) | EP3406257B1 (https=) |
| JP (2) | JP6317324B2 (https=) |
| CN (2) | CN104271146A (https=) |
| AU (2) | AU2013237827B2 (https=) |
| CA (1) | CA2869080C (https=) |
| DK (1) | DK2830644T3 (https=) |
| WO (1) | WO2013149172A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2788013A4 (en) * | 2011-12-09 | 2015-08-19 | Stealth Peptides Int Inc | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
| CN104271146A (zh) * | 2012-03-30 | 2015-01-07 | 康肽德生物医药技术有限公司 | 用于预防和治疗神经病的方法和组合物 |
| WO2017180535A1 (en) | 2016-04-11 | 2017-10-19 | Carnot, Llc | Chiral peptides |
| EP3500286A4 (en) * | 2016-08-16 | 2020-03-25 | Stealth BioTherapeutics Corp | N-CARBOXYANHYDRIDE-BASED SCALE SYNTHESIS OF ELAMIPRETID |
| US11034724B2 (en) | 2017-04-05 | 2021-06-15 | Stealth Biotherapeutics Corp. | Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2 |
| US10676506B2 (en) | 2018-01-26 | 2020-06-09 | Stealth Biotherapeutics Corp. | Crystalline bis- and tris-hydrochloride salt of elamipretide |
| CN112961249B (zh) * | 2021-02-25 | 2023-08-04 | 兰州大学 | 一类基于阿片肽和大麻肽的双功能肽及其制备方法与应用 |
| WO2024253189A1 (ja) * | 2023-06-09 | 2024-12-12 | 国立大学法人 富山大学 | がん化学療法剤に起因する末梢神経障害の予防剤及び／又は改善剤 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5913318A (ja) | 1982-07-13 | 1984-01-24 | 株式会社村田製作所 | 電子部品の製造方法 |
| US5786332A (en) * | 1995-03-06 | 1998-07-28 | Trega Biosciences, Inc. | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels |
| US6376467B1 (en) * | 1998-10-09 | 2002-04-23 | The Regents Of The University Of California | Use of inhibitors of protein kinase C epsilon to treat pain |
| CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| EP1599216B9 (en) * | 2003-02-04 | 2015-02-11 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
| CA3024434A1 (en) * | 2004-01-23 | 2005-08-11 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| CN104788540B (zh) * | 2005-09-16 | 2019-10-18 | 科内尔研究基金会 | 用于减少cd36表达的方法 |
| EP2712620A1 (en) | 2008-02-07 | 2014-04-02 | Cornell University | Methods for Preventing or Treating Insulin Resistance |
| EP3741381B1 (en) * | 2008-02-26 | 2024-04-24 | Cornell University | A peptide for use for prevention and treatment of acute renal injury |
| US20100331265A1 (en) * | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
| WO2011019809A1 (en) * | 2009-08-12 | 2011-02-17 | Cornell University | Methods for preventing or treating metabolic syndrome |
| ES2964555T3 (es) * | 2009-08-24 | 2024-04-08 | Stealth Biotherapeutics Inc | Péptido para uso en la prevención o tratamiento de la degeneración macular |
| WO2011044044A1 (en) * | 2009-10-05 | 2011-04-14 | Cornell University | Methods for the prevention or treatment of heart failure |
| EP3266462A1 (en) * | 2009-12-31 | 2018-01-10 | Stealth Peptides International, Inc. | Methods for performing a coronary artery bypass graft procedure |
| EP3090754A1 (en) * | 2009-12-31 | 2016-11-09 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of vessel occlusion injury |
| CA2787331A1 (en) * | 2010-01-25 | 2011-07-28 | Hazel H. Szeto | Aromatic-cationic peptides and uses of same |
| JP2013521231A (ja) * | 2010-02-26 | 2013-06-10 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド | ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する |
| EP3375449A1 (en) * | 2010-03-15 | 2018-09-19 | Stealth Peptides International, Inc. | Combination therapies using cyclosporine and aromatic cationic peptides |
| EP2590664B1 (en) * | 2010-07-09 | 2019-03-27 | Stealth Peptides International, Inc. | Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury |
| US20120083452A1 (en) * | 2010-09-30 | 2012-04-05 | Perricone Nicholas V | Topical Anesthetic Uses of Szeto-Schiller Peptides |
| KR101351432B1 (ko) | 2011-12-27 | 2014-01-15 | 에스케이씨 주식회사 | 초미세 발포 폴리우레탄 탄성체의 제조방법 |
| CN104271146A (zh) * | 2012-03-30 | 2015-01-07 | 康肽德生物医药技术有限公司 | 用于预防和治疗神经病的方法和组合物 |
-
2013
- 2013-03-29 CN CN201380023997.6A patent/CN104271146A/zh active Pending
- 2013-03-29 JP JP2015503653A patent/JP6317324B2/ja active Active
- 2013-03-29 WO PCT/US2013/034647 patent/WO2013149172A1/en not_active Ceased
- 2013-03-29 CN CN201710226838.6A patent/CN107320712A/zh active Pending
- 2013-03-29 AU AU2013237827A patent/AU2013237827B2/en active Active
- 2013-03-29 US US14/388,705 patent/US9636378B2/en active Active
- 2013-03-29 EP EP18169371.4A patent/EP3406257B1/en active Active
- 2013-03-29 EP EP13769696.9A patent/EP2830644B1/en active Active
- 2013-03-29 EP EP16192386.7A patent/EP3170506B1/en active Active
- 2013-03-29 DK DK13769696.9T patent/DK2830644T3/en active
- 2013-03-29 CA CA2869080A patent/CA2869080C/en active Active
-
2017
- 2017-04-17 US US15/488,697 patent/US10279008B2/en active Active
- 2017-11-21 AU AU2017265013A patent/AU2017265013B9/en active Active
-
2018
- 2018-03-29 JP JP2018063574A patent/JP2018123143A/ja active Pending
-
2019
- 2019-04-22 US US16/390,799 patent/US10646539B2/en active Active
-
2020
- 2020-04-07 US US16/842,040 patent/US20200397850A1/en not_active Abandoned
-
2022
- 2022-03-01 US US17/684,057 patent/US11998585B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512420A5 (https=) | ||
| JP2010270124A5 (https=) | ||
| NZ708506A (en) | Methods of treating bladder cancer | |
| FI3562486T3 (fi) | Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa | |
| JP2019206593A5 (https=) | ||
| HK1247835A1 (zh) | 甲状旁腺功能减退症的治疗 | |
| EA201491358A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| WO2013123215A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| JP2013527232A5 (https=) | ||
| JP2016512506A5 (https=) | ||
| BR112013022044A2 (pt) | veículo mastigável para absorção na boca | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2019521180A5 (https=) | ||
| WO2009029622A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
| JP2013542205A5 (https=) | ||
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| JP2011515481A5 (https=) | ||
| JP2013509441A5 (https=) | ||
| JP2016530291A5 (https=) | ||
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| JP2018522028A5 (https=) |